Norditropin NordiFlex 15 mg/1.5 ml Norra - norra - Statens legemiddelverk

norditropin nordiflex 15 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 15 mg/1.5 ml

Norditropin NordiFlex 5 mg/1.5 ml Norra - norra - Statens legemiddelverk

norditropin nordiflex 5 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 5 mg/1.5 ml

Norditropin NordiFlex 10 mg/1.5 ml Norra - norra - Statens legemiddelverk

norditropin nordiflex 10 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 10 mg/1.5 ml

Carexarit 25 mikrog Norra - norra - Statens legemiddelverk

carexarit 25 mikrog

2care4 generics aps - klonidinhydroklorid - tablett, drasjert - 25 mikrog

Carmustine Macure 100 mg Norra - norra - Statens legemiddelverk

carmustine macure 100 mg

macure pharma aps - karmustin - pulver og væske til konsentrat til infusjonsvæske, oppløsning - 100 mg

Ngenla Euroopa Liit - norra - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Orgovyx Euroopa Liit - norra - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - prostata neoplasmer - endokrin terapi - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Sorafenib Accord Euroopa Liit - norra - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiske midler - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Qaialdo Euroopa Liit - norra - EMA (European Medicines Agency)

qaialdo

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 og 5.

Orbeseal vet 2.6 g/4 g Norra - norra - Statens legemiddelverk

orbeseal vet 2.6 g/4 g

zoetis finland oy - vismutsubnitrat, tungt - intramammarie, suspensjon - 2.6 g/4 g